Delivery Order SPE2DB22D2211-SPE2DB25FSEMJ
- Not listed
- The Defense Logistics Agency awarded a $143,366.66 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 9, 2025, with an ultimate completion date of September 10, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a $102,781.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes, with an ultimate completion date of August 6, 2025. This non-set-aside contract was competitively awarded and represents a single delivery order fulfilling federal medical supply requirements. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $4,212.40 to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This firm fixed-price delivery order is scheduled for completion by September 9, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's established capability to meet federal...
- The Defense Logistics Agency awarded a delivery order valued at approximately $120,283 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 micrograms per 0.5 milliliter syringes. The contract, awarded on September 4, 2025, with an ultimate completion date of September 5, 2025, represents a firm fixed price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform at its corporate office...
- The Defense Logistics Agency awarded a $139,894.18 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 22, 2025, with completion scheduled for July 23, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The work will be performed at...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $134,719.00 on August 27, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 28, 2025. The product will be delivered to AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $9,743.10 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 4, 2025, with completion scheduled for September 5, 2025. This non-set-aside, firm fixed-price delivery order represents a single pharmaceutical procurement supporting federal medical supply needs. The award was made through competitive procurement processes to the prime contractor, whose corporate office is located in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $38,637.55 to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes with an ultimate completion date of September 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine approved for use in adults,...
- The Defense Logistics Agency awarded a delivery order valued at $4,890.36 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 29, 2025, with completion targeted for September 2, 2025. This competitively awarded, non-set-aside contract represents a firm fixed-price delivery order for the hepatitis B vaccine product, with performance to be executed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award is issued as a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $105,310.00 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 23, 2025, with completion targeted for July 24, 2025. This firm fixed price delivery order was awarded without set-aside designation through competitive procurement. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSEMJDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,684.96 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 8, 2025, with completion scheduled for September 9, 2025. This delivery order is structured under a firm fixed price contract type with no set-aside designation, indicating competitive award. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, which serves as the company's headquarters and primary distribution center for federal medical procurement. This delivery order represents a task against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical support vehicle running through December 2026. HEPLISAV-B is a recombinant zoster vaccine used for adult immunization and reflects the breadth of pharmaceutical products AmerisourceBergen supplies to support military healthcare systems globally. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen maintains extensive contract relationships with the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems, fulfilling diverse medical supply requirements ranging from specialty medications and vaccines to medical devices across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 9/8/25 |